Robert Provenzano

Oral Hypoxia–Inducible Factor Prolyl Hydroxylase Inhibitor Roxadustat (FG-4592) for the Treatment of Anemia in Patients with CKD

Robert Provenzano, Anatole Besarab, Chao Sun et al. · Clinical Journal of the American Society of Nephrology · 2016 · 293 citations · Full text

Medicine, Hematology, Pharmacotherapy +14

Randomized placebo-controlled dose-ranging and pharmacodynamics study of roxadustat (FG-4592) to treat anemia in nondialysis-dependent chronic kidney disease (NDD-CKD) patients

Anatole Besarab, Robert Provenzano, Joachim Hertel et al. · Nephrology Dialysis Transplantation · 2015 · 279 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +13

Roxadustat (FG-4592) Versus Epoetin Alfa for Anemia in Patients Receiving Maintenance Hemodialysis: A Phase 2, Randomized, 6- to 19-Week, Open-Label, Active-Comparator, Dose-Ranging, Safety and Exploratory Efficacy Study

Robert Provenzano, Anatole Besarab, Steven Charles Wright et al. · American Journal of Kidney Diseases · 2016 · 256 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17

Ferumoxytol as an Intravenous Iron Replacement Therapy in Hemodialysis Patients

Robert Provenzano, Brigitte Schiller, Madhumathi Rao et al. · Clinical Journal of the American Society of Nephrology · 2009 · 182 citations

Medicine, Hematology, Pharmacotherapy +17

Roxadustat for anemia in patients with end-stage renal disease incident to dialysis

Robert Provenzano, Evgeny Shutov, Svitlana Korneyeva et al. · Nephrology Dialysis Transplantation · 2021 · 127 citations

Medicine, Hematology, Pharmacotherapy +15